vs
Side-by-side financial comparison of PERRIGO Co plc (PRGO) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $853.7M, roughly 1.3× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 23.1% vs -127.8%, a 150.9% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (11.0% vs -2.5%). Over the past eight quarters, Primerica, Inc.'s revenue compounded faster (7.2% CAGR vs 1.3%).
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
PRGO vs PRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $853.7M |
| Net Profit | $-1.4B | $197.0M |
| Gross Margin | 32.6% | — |
| Operating Margin | -116.0% | 28.9% |
| Net Margin | -127.8% | 23.1% |
| Revenue YoY | -2.5% | 11.0% |
| Net Profit YoY | -3093.9% | 17.9% |
| EPS (diluted) | $-10.23 | $6.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $853.7M | ||
| Q3 25 | $1.0B | $839.9M | ||
| Q2 25 | $1.1B | $793.3M | ||
| Q1 25 | $1.0B | $804.8M | ||
| Q4 24 | $1.1B | $768.8M | ||
| Q3 24 | $1.1B | $774.1M | ||
| Q2 24 | $1.1B | $803.4M | ||
| Q1 24 | $1.1B | $742.8M |
| Q4 25 | $-1.4B | $197.0M | ||
| Q3 25 | $7.5M | $206.8M | ||
| Q2 25 | $-8.4M | $178.3M | ||
| Q1 25 | $-6.4M | $169.1M | ||
| Q4 24 | $-44.4M | $167.1M | ||
| Q3 24 | $-21.0M | $164.4M | ||
| Q2 24 | $-108.4M | $1.2M | ||
| Q1 24 | $2.0M | $137.9M |
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | 98.0% | ||
| Q1 24 | 33.1% | 98.2% |
| Q4 25 | -116.0% | 28.9% | ||
| Q3 25 | 7.0% | 32.3% | ||
| Q2 25 | 4.3% | 29.6% | ||
| Q1 25 | 4.5% | 27.5% | ||
| Q4 24 | 10.0% | 64.7% | ||
| Q3 24 | 7.4% | 32.9% | ||
| Q2 24 | -2.5% | 1.0% | ||
| Q1 24 | -5.1% | 24.1% |
| Q4 25 | -127.8% | 23.1% | ||
| Q3 25 | 0.7% | 24.6% | ||
| Q2 25 | -0.8% | 22.5% | ||
| Q1 25 | -0.6% | 21.0% | ||
| Q4 24 | -3.9% | 21.7% | ||
| Q3 24 | -1.9% | 21.2% | ||
| Q2 24 | -10.2% | 0.1% | ||
| Q1 24 | 0.2% | 18.6% |
| Q4 25 | $-10.23 | $6.11 | ||
| Q3 25 | $0.05 | $6.35 | ||
| Q2 25 | $-0.06 | $5.40 | ||
| Q1 25 | $-0.05 | $5.05 | ||
| Q4 24 | $-0.32 | $4.92 | ||
| Q3 24 | $-0.15 | $4.83 | ||
| Q2 24 | $-0.79 | $0.03 | ||
| Q1 24 | $0.01 | $3.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $756.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.9B | $2.4B |
| Total Assets | $8.5B | $15.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $756.2M | ||
| Q3 25 | $432.1M | $644.9M | ||
| Q2 25 | $454.2M | $621.2M | ||
| Q1 25 | $409.9M | $625.1M | ||
| Q4 24 | $558.8M | $687.8M | ||
| Q3 24 | $1.5B | $550.1M | ||
| Q2 24 | $542.8M | $627.3M | ||
| Q1 24 | $658.5M | $593.4M |
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | $4.4B | $2.3B | ||
| Q2 25 | $4.5B | $2.3B | ||
| Q1 25 | $4.4B | $2.3B | ||
| Q4 24 | $4.3B | $2.3B | ||
| Q3 24 | $4.6B | $1.9B | ||
| Q2 24 | $4.5B | $2.1B | ||
| Q1 24 | $4.7B | $2.2B |
| Q4 25 | $8.5B | $15.0B | ||
| Q3 25 | $10.1B | $14.8B | ||
| Q2 25 | $10.1B | $14.8B | ||
| Q1 25 | $9.8B | $14.6B | ||
| Q4 24 | $9.6B | $14.6B | ||
| Q3 24 | $11.2B | $14.8B | ||
| Q2 24 | $10.4B | $14.6B | ||
| Q1 24 | $10.6B | $14.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.4M | $338.2M |
| Free Cash FlowOCF − Capex | $148.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.4M | $338.2M | ||
| Q3 25 | $51.7M | $202.9M | ||
| Q2 25 | $75.9M | $162.6M | ||
| Q1 25 | $-64.5M | $197.5M | ||
| Q4 24 | $312.6M | $270.6M | ||
| Q3 24 | $42.2M | $207.3M | ||
| Q2 24 | $9.5M | $173.3M | ||
| Q1 24 | $-1.4M | $210.9M |
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-26.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — | ||
| Q1 24 | -2.4% | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.3% | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | 6.89× | 0.98× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 1.62× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 147.98× | ||
| Q1 24 | -0.70× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
